Get started
Author

G.-C. Chang

Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
2014 · Z. Wang, B. Zhu, et al. · Human Molecular Genetics · 105
Anti- -enolase Autoantibodies Are Down-regulated in Advanced Cancer Patients
2010 · N.-Y. Shih, H.-L. Lai, et al. · Japanese Journal of Clinical Oncology · 53
PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
2025 · A.E. Drilon, B.C. Cho, et al. · Journal of Thoracic Oncology · 9
Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma
2014 · T.S.K. Mok, E. Tan, et al. · Annals of Oncology · 4
6526 POSTER Review of pulmonary haemorrhage (PH) in non-small cell lung cancer (NSCLC) subjects receiving bevacizumab and cisplatin plus gemcitabine on protocol BO17704
2007 · V. Hirsh, J. Bennouna, et al. · European Journal of Cancer Supplements · 3
Baseline results of lung cancer screening program for family lung cancer risk with low-dose spiral CT in Taiwan.
2010 · C. Wang, Y. Tsai, et al. · Journal of Clinical Oncology · 2
PL03.06: Zidesamtinib in TKI-naive Patients with Advanced/Metastatic ROS1+ NSCLC: ARROS-1 Efficacy and Safety Data
2026 · A. Drilon, A.J. de Langen, et al. · Journal of Thoracic Oncology · 1
OFP01.01 Liquid Biopsy to Detect MET Alterations in Patients with Advanced NSCLC: Biomarker Analysis from the VISION Study
2021 · X. Le, D. Kowalski, et al. · Journal of Thoracic Oncology · 1
PDF
P1.375: Clinical Characteristics, Genomic Subtypes, and Outcomes of HER2-Altered NSCLC: A Multicenter Real-World Study in Taiwan
2026 · Y.-H. Luo, J.-S. Tseng, et al. · Journal of Thoracic Oncology
P3.378: First-Line Treatment of Tislelizumab Plus Paclitaxel-Albumin/Carboplatin for Advanced Thymic Carcinoma: A Phase II Trial
2026 · L. Zhou, X. Yan, et al. · Journal of Thoracic Oncology
P2.389: Biomarker-Directed Therapy for Distant Recurrence After Adjuvant Osimertinib in Egfrm Resectable Stage IB-IIIA NSCLC (REVIVE)
2026 · X. Yan, L. Zhou, et al. · Journal of Thoracic Oncology
EP13.49 Prognosis of Perioperative Therapy in Primary Limited-Stage Small-Cell Lung Cancer
2025 · G. Chang, J. Yan, et al. · Journal of Thoracic Oncology
179TiP: Lorlatinib as neoadjuvant treatment in stage IB-IIIB ALK-rearranged non-small cell lung cancer (NEOLORA)
2025 · F. Yang, X. Yan, et al. · Journal of Thoracic Oncology
PDF
P2.23-04 Changes in Physical Activity, Fatigue, and Six-Minute Walk Distance Among Lung Cancer Patients Before and After Chemotherapy
2023 · P.-H. Chang, Y.-H. Lai, et al. · Journal of Thoracic Oncology
PDF
P21.12 An Observational Study of Treatment Outcome in Stage III Lung Cancer Patients in Taiwan: KINDLE study
2021 · P. Su, S. Hsiao, et al. · Journal of Thoracic Oncology
PDF
Supplementary Material for: Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
2020 · Tseng, J.-S., Hsu, K.-H., et al. · Figshare
CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
2019 · B.C. Cho, G.-C. Chang, et al. · Annals of Oncology
PDF
ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
2018 · H.C. Freitas, K. Park, et al. · Annals of Oncology
Works count: 18
Citation count: 178
H-index: 4
I10-index: 2
Year
Topic
Type